The development, testing, and use of a novel excipient as part of its formulation enabled MannKind to develop a viable inhaled insulin product after other firms’ insulin inhalation projects had not been successful.
At the American Association of Pharmaceutical Scientists (AAPS) National Biotech Conference (NBC) in early June in San Francisco, MannKind Director of Pharmaceutical Research Kelly Kraft discussed her firm’s development of its inhaled insulin product Afrezza, the product’s advantages over injected insulin, the importance of the novel excipient involved to the product’s functionality, and the process used to get the excipient approved.
The excipient is what gives the powder the characteristics to get into the lung, Kraft explained.  Without that particular excipient, “we do not have a product.”
[CLICK HERE for the complete story. Â Nonsubscribers can get information on IPQ subscription/licensing and individual story purchasing by contacting Jonathan Trethowan (Jonathan@ipq.org).]
